The Motley Fool

These FTSE 100 stocks slumped badly in 2019. Here’s what I’d do now

The FTSE 100 has certainly been through a year of contrasts, with some impressively high flyers soaring in 2019, but there were some depressing falls too.


On the final day, it’s a one-on-one clash between NMC Health (which wasn’t even in the running until December’s big crash) and Centrica (LSE: CNA), both down around 34% at the time of writing.

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!

Centrica’s fall has been longer in the making, with the shares down 66% over five years as the British Gas owner suffered multiple blows including falling customer numbers, the energy price cap, and pressure on its upstream exploration and production business.

According to forecasts, this year will see earnings per share having dropped by 60% since 2014, and earlier in 2019 the company slashed its dividend from 2018’s 12p per share to 5p — but that would still yield 5.5%. Analysts are finally forecasting a return to an earnings rise in 2020, which would drop the P/E to approximately 10.

I’m wary of recovery stocks, but is Centrica on the turnaround? I think there are signs it is. For one thing, the share price has actually been recovering in recent months and is up 40% since August’s lowest point — helped by the Conservative Party’s election victory that put paid to Jeremy Corbyn’s nationalisation plans.

I could be tempted, but the company is still in the restructuring phase of its recovery plan and is disposing of non-core assets. And the real measure of success won’t be seen until the new slimmer company starts showing repeatable earnings growth. I think I’ll wait a while and at least see how things go in 2020.


Shares in Pearson (LSE: PSON) have fallen almost as much as Centrica’s in 2019 with a drop of 31%, and their five-year loss of 45% looks almost desirable compared to the energy firm’s slump.

The publisher has suffered from a fall in demand for its traditional products, and it’s been working on remaking itself as an online educator. But it’s been slow progress, and the pending departure of the CEO doesn’t look like a particularly good omen to me.

But Pearson is selling its remaining stake in Penguin Random House for £530m (after some other big disposals), and that amount of cash will give it some breathing room. It will also leave a surplus to the tune of £350m, which the company will use for a share buyback.

A buyback suggests the board sees the shares as undervalued now, so that might inject a bit of confidence. But I’m really not sure I agree. On a forward P/E of 11.5 for 2019, rising to 12 on 2020 forecasts, the shares don’t look an obviously cheap buy to me.

It probably adds a bit of support for the dividend, currently set to yield 3.1%, but if the shares keep on falling into 2020, then the buyback might turn out to be badly timed.

I also fear the online focus will hit some heavy competition, which should mean tighter margins, and I’m not seeing where the competitive advantage lies.

While I think 2020 could see a continued upswing for Centrica shares, I’m not optimistic for the Pearson price.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended NMC Health. The Motley Fool UK has recommended Pearson. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.